Functional improvement and correlations with symptomatic improvement in adults with attention deficit hyperactivity disorder receiving long-acting methylphenidate
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Background: Data on the relationship between core symptoms and daily functioning in adults with attention deficit hyperactivity disorder (ADHD) are limited. Daily functioning was assessed as part of an open-label extension, and associations with symptom scores were evaluated. Method: After a 5-week double-blind study with adults with ADHD receiving osmotic-controlled release oral delivery system (OROS) methylphenidate (MPH) 18, 36 or 72 mg/day, or placebo, participants were eligible for a 7-week open-label extension in which all patients received OROS MPH. Data for the Conners' Adult ADHD Rating Scale – Observer: Screening Version (CAARS-O:SV) (primary endpoint) have been presented previously. Secondary endpoints included the observer self-reported short version of the CAARS (CAARS-S:S) and the Clinical Global Impressions – Severity Scale (CGI-S). Daily functioning and quality of life were assessed using the Sheehan Disability Scale (SDS) and the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) respectively. In post-hoc analyses, changes in CAARS-O:SV were evaluated in subgroups. Relationships between symptom and functional outcomes were evaluated in a multivariate regression analysis. Results: A total of 370 patients entered the open-label extension. Significant improvements from baseline in CAARS-O:SV were similar regardless of sex, ADHD subtype, prior treatment or psychiatric co-morbidity. Significant improvements from double-blind baseline were also seen for the CAARS-S:S, CGI-S, SDS and Q-LES-Q. Improvements in the CAARS-O:SV Hyperactivity/Impulsivity subscale were associated with improvements in SDS total and subscale scores, and in the Q-LES-Q score at open-label endpoint. Improvements in CAARS-O:SV Inattention subscale and CGI-S scores were not significantly associated with functional changes. Conclusions: Improvements in ADHD symptoms relating to hyperactivity and impulsivity in adults receiving OROS MPH are associated with improvements in daily functioning and quality of life.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sheehan, D. V., Harnett-Sheehan, K., & Raj, B. A. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199606003-00015 · Cited by 1,440
Lijffijt, M., Kenemans, J. L., Verbaten, M. N., & van Engeland, H. (2005) · Journal of Abnormal Psychology · doi:10.1037/0021-843x.114.2.216 · Cited by 592 · cited 2×
“…(ADHD) experience deficits in executive function, including inhibition of motor impulses, verbal fluency, working memory, planning, organization and cognitive flexibility (Barkley, 1998 ; Woods et al. 2002 ; Hervey et al. 2004 ; Roth & Saykin, 2004 ; Boonstra et al. 2005b ; Lijffijt et al. 2005).”
BackgroundExecutive functioning in adult ADHD: a meta-analytic review
MARIJE BOONSTRA, A., OOSTERLAAN, J., SERGEANT, J. A., & BUITELAAR, J. K. (2005) · Psychological Medicine · doi:10.1017/s003329170500499x · Cited by 560 · cited 3×
“…(ADHD) experience deficits in executive function, including inhibition of motor impulses, verbal fluency, working memory, planning, organization and cognitive flexibility (Barkley, 1998 ; Woods et al. 2002 ; Hervey et al. 2004 ; Roth & Saykin, 2004 ; Boonstra et al. 2005b ; Lijffijt et al. 2005).”
BackgroundSelf-citationWolraich, M. L., Greenhill, L. L., Pelham, W., Swanson, J., Wilens, T., Palumbo, D., Atkins, M., McBurnett, K., Bukstein, O., August, G., et al. (2001) · Pediatrics · doi:10.1542/peds.108.4.883 · Cited by 502
Faraone, S. V., Spencer, T., Aleardi, M., Pagano, C., & Biederman, J. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000108984.11879.95 · Cited by 404
Pelham, W. E., Gnagy, E. M., Burrows-Maclean, L., Williams, A., Fabiano, G. A., Morrisey, S. M., Chronis, A. M., Forehand, G. L., Nguyen, C. A., Hoffman, M. T., et al. (2001) · Pediatrics · doi:10.1542/peds.107.6.e105 · Cited by 378 · cited 5×
“Studies have shown that once-daily treatment with OROS MPH is effective and well tolerated for treatment of ADHD in children and adolescents (Pelham et al. 2001 ; Wolraich et al. 2001 ; Swanson et al. 2003), and adults (Biederman et al. 2006 ; Medori et al. 2008 ; Adler et al. 2009 ; Buitelaar et…”
BackgroundMethodInfluentialAssessing impairment in patients with panic disorder: the Sheehan Disability Scale
Leon, A. C., Shear, M. K., Portera, L., & Klerman, G. L. (1992) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/bf00788510 · Cited by 319 · cited 2×
“…it has been validated in patients with bipolar disorder (Arbuckle et al. 2009), social anxiety disorder (Hambrick et al. 2004) and panic disorder (Leon et al. 1992), and has been shown to be sensitive to treatment effects in patients with anxiety disorders, depression or premenstrual dysphoric…”
BackgroundBiederman, J., Mick, E., Surman, C., Doyle, R., Hammerness, P., Harpold, T., Dunkel, S., Dougherty, M., Aleardi, M., & Spencer, T. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.09.011 · Cited by 267
Swanson, J., Gupta, S., Lam, A., Shoulson, I., Lerner, M., Modi, N., Lindemulder, E., & Wigal, S. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.2.204 · Cited by 248
Medori, R., Ramos-Quiroga, J. A., Casas, M., Kooij, J. J. S., Niemelä, A., Trott, G.-E., Lee, E., & Buitelaar, J. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.11.008 · Cited by 186 · cited 7×
“Stimulant medications such as methylphenidate (MPH) are highly effective for treatment of the core ADHD symptoms (Faraone et al. 2004 ; Medori et al. 2008 ; Peterson et al. 2008 ; Adler et al. 2009 ; Buitelaar et al. 2009a).”
BackgroundMethodInfluentialSelf-citation
Cited by
Gender differences in adults with attention-deficit/hyperactivity disorder: A narrative review
Williamson, D., & Johnston, C. (2015) · Clinical Psychology Review · doi:10.1016/j.cpr.2015.05.005 · Cited by 226
Fredriksen, M., Halmøy, A., Faraone, S. V., & Haavik, J. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.07.016 · Cited by 173
Do stimulants improve functioning in adults with ADHD?
Surman, C. B. H., Hammerness, P. G., Pion, K., & Faraone, S. V. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.02.010 · Cited by 47
“Similarly, the Sheehan Disability Scale was sensitive to improvements in the work, social life and leisure activities, home life and family responsibilities domains of that scale in a population participating in a short double-blind and short openlabel extension treatment with low dose (up to 72 mg) OROSmethylphenidat…”
MethodWeisler, R., Ginsberg, L., Dirks, B., Deas, P., Adeyi, B., & Adler, L. A. (2017) · Journal of Attention Disorders · doi:10.1177/1087054713518242 · Cited by 15
Childress, A. C., Cutler, A. J., Saylor, K., Gasior, M., Hamdani, M., Ferreira-Cornwell, M. C., & Findling, R. L. (2014) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2013.0077 · Cited by 5
Metadata
- Authors
- Buitelaar, J. K., Casas, M., Philipsen, A., Kooij, J. J. S., Ramos-Quiroga, J. A., Dejonckheere, J., van Oene, J. C., & Schäuble, B.
- Venue
- Psychological Medicine
- Publisher
- Cambridge University Press (CUP)
- Published
- 2011-06-01
- Volume
- 42
- Issue
- 1
- Pages
- 195-204
- ISSN
- 0033-2917 (ISSN-L)
- 1469-8978
- OpenAlex
- W2138818661
- Cited by
- 28
- References
- 21
- FWCI
- 2.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Functional improvement and correlations with symptomatic improvement in adults with attention deficit hyperactivity disorder receiving long-acting methylphenidate. https://app.cochat.ai/papers/10.1017/s0033291711000845
- The paper
- Buitelaar, J. K., Casas, M., Philipsen, A., Kooij, J. J. S., Ramos-Quiroga, J. A., Dejonckheere, J., van Oene, J. C., & Schäuble, B. (2012). Functional improvement and correlations with symptomatic improvement in adults with attention deficit hyperactivity disorder receiving long-acting methylphenidate. Psychological Medicine. https://doi.org/10.1017/s0033291711000845
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.